Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy. …
TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy
October 9, 2024 Australian Biotech
Latest Video
New Stories
-
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News -
It was an unintentionally revealing discussion about the history and reality of agreements
June 9, 2026 - - Latest News -
R&D tax shake up risks sending Australia’s biotech talent and jobs overseas
June 9, 2026 - - Latest News -
Rare Cancers Australia co-founder Kate Vines recognised in King's Birthday Honours
June 8, 2026 - - Latest News -
Omico is evolving tumour genomics into hard evidence for precision oncology
June 8, 2026 - - Latest News -
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News